Department of Surgery, Weill Cornell Medicine, New York, NY, USA.
Center for Genomic Health, Weill Cornell Medicine, New York, NY, USA.
Nat Cell Biol. 2023 Mar;25(3):381-389. doi: 10.1038/s41556-023-01095-y. Epub 2023 Mar 13.
COVID-19 is a systemic disease involving multiple organs. We previously established a platform to derive organoids and cells from human pluripotent stem cells to model SARS-CoV-2 infection and perform drug screens. This provided insight into cellular tropism and the host response, yet the molecular mechanisms regulating SARS-CoV-2 infection remain poorly defined. Here we systematically examined changes in transcript profiles caused by SARS-CoV-2 infection at different multiplicities of infection for lung airway organoids, lung alveolar organoids and cardiomyocytes, and identified several genes that are generally implicated in controlling SARS-CoV-2 infection, including CIART, the circadian-associated repressor of transcription. Lung airway organoids, lung alveolar organoids and cardiomyocytes derived from isogenic CIART human pluripotent stem cells were significantly resistant to SARS-CoV-2 infection, independently of viral entry. Single-cell RNA-sequencing analysis further validated the decreased levels of SARS-CoV-2 infection in ciliated-like cells of lung airway organoids. CUT&RUN, ATAC-seq and RNA-sequencing analyses showed that CIART controls SARS-CoV-2 infection at least in part through the regulation of NR4A1, a gene also identified from the multi-organoid analysis. Finally, transcriptional profiling and pharmacological inhibition led to the discovery that the Retinoid X Receptor pathway regulates SARS-CoV-2 infection downstream of CIART and NR4A1. The multi-organoid platform identified the role of circadian-clock regulation in SARS-CoV-2 infection, which provides potential therapeutic targets for protection against COVID-19 across organ systems.
COVID-19 是一种涉及多个器官的系统性疾病。我们之前建立了一个从人类多能干细胞中衍生类器官和细胞的平台,用于模拟 SARS-CoV-2 感染并进行药物筛选。这为细胞嗜性和宿主反应提供了深入了解,但调节 SARS-CoV-2 感染的分子机制仍未得到充分定义。在这里,我们系统地检查了 SARS-CoV-2 在不同感染复数下对肺气道类器官、肺肺泡类器官和心肌细胞感染的转录谱变化,并鉴定了几个通常与控制 SARS-CoV-2 感染有关的基因,包括 CIART,即转录的昼夜相关抑制剂。来自同基因 CIART 人类多能干细胞的肺气道类器官、肺肺泡类器官和心肌细胞对 SARS-CoV-2 感染具有显著的抗性,与病毒进入无关。单细胞 RNA-seq 分析进一步验证了 SARS-CoV-2 在肺气道类器官纤毛样细胞中的感染水平降低。CUT&RUN、ATAC-seq 和 RNA-seq 分析表明,CIART 通过调节 NR4A1 至少部分控制 SARS-CoV-2 感染,NR4A1 也是从多器官分析中鉴定出来的基因。最后,转录谱分析和药理学抑制导致发现视黄酸 X 受体途径在 CIART 和 NR4A1 下游调节 SARS-CoV-2 感染。多器官平台确定了生物钟调节在 SARS-CoV-2 感染中的作用,这为跨器官系统预防 COVID-19 提供了潜在的治疗靶点。